TAILORx Trial: What It Means For You
The landmark TAILORx clinical trial, presented at the 2018 American Society of Clinical Oncology meeting in early June, showed that not all women with early-stage, hormone receptor-positive, HER2-negative breast cancer need chemotherapy treatment. But the results of the trial are complex and may be hard to understand.
Join us for this free one-hour webinar to hear our expert, Angela DeMichele, MD, MSCE, explain the results of TAILORx, how the trial was designed and what its findings mean for you. Listeners will learn more about the OncotypeDX test, what its scores mean, how age impacts your choices and how it can help your doctors determine the most appropriate treatment.
Dr. DeMichele will use the first 40-45 minutes to give a presentation. The last 15-20 minutes will be a moderated Q&A session. We will take questions via phone and online chat.
About Our Speaker:
Angela M. DeMichele, MD, MSCE
Co-Leader, Breast Cancer Research Program
Abramson Cancer Center
Professor of Epidemiology in Biostatistics and Epidemiology
University of Pennsylvania
Dr. DeMichele is a senior scholar in the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania, as well as the co-director of the breast cancer program at the Abramson Cancer Center. She is a member of LBBC’s Medical Advisory Board and frequently speaks for us and reviews our publications. Read more.